ABCB11 and metabolic dysfunction-associated steatotic liver disease: Ilexsaponin A1 ameliorated NAFLD by upregulating alternative BA synthesis CYP27A1/CYP7B1, enhancing hepatic efflux via FXR/BSEP, reducing NTCP-dependent reabsorption, and promoting fecal excretion via BSH activity, thereby lowering serum cholesterol, hepatic steatosis, and BA accumulation (Zhao et al., 2021).